TIDMPXS
RNS Number : 8164N
Provexis PLC
01 October 2021
1 October 2021
Provexis plc
('Provexis' or the 'Company')
Grant of Share Options
Provexis, the business that develops, licenses and sells the
proprietary, scientifically-proven Fruitflow(R) heart-health
functional food ingredient, announces that it has today awarded a
total of 10,000,000 options ('Options') over ordinary shares of 0.1
pence each in the Company ('Ordinary Shares') under the Provexis
2005 share option scheme to certain scientific, sales and marketing
consultants to the Company.
These Options will have an exercise price of 0.80 pence, being
the closing mid-market price on 30 September 2021. The Options are
exercisable, subject to vesting, between 1 April 2024 and 10 years
from the date of grant.
Following the issue of the new Options, the total number of
Ordinary Shares under option which could be issued if all of the
performance criteria are met is 178,500,000 Ordinary Shares,
representing 8.1 per cent. of the Company's issued share
capital.
For further information please contact:
Provexis plc Tel: 07490 391888
Ian Ford, CEO enquiries@provexis.com
Dawson Buck, Chairman
Allenby Capital Limited Tel: 020 3328 5656
Nick Naylor / Liz Kirchner
Notes for editors
About Provexis plc
AIM-listed Provexis is focused on the development, licensing and
sales of its proprietary, scientifically-proven Fruitflow(R)
heart-health functional food ingredient.
Fruitflow is a natural, breakthrough ingredient that helps with
platelet aggregation. This helps promote normal blood flow and
circulation, which in turn benefits cardiovascular health.
Fruitflow helps the platelets to circulate freely and smoothly
throughout your blood, without sticking to one another or to the
blood vessels themselves. Freely flowing blood helps reduce stress
on your cardiovascular system.
Fruitflow is a highly concentrated form of bioactives which is
lycopene-free and contains over 30 known anti-platelet compounds.
Published clinical studies have shown that Fruitflow works to
maintain healthy blood flow in a similar way to 75mg aspirin but
with a milder and reversible action; Fruitflow has a similar
antiplatelet effect to a single dose of aspirin - but when taken
daily, it has none of aspirin's side effects.
The science behind Fruitflow has been validated by leading peer
review publications and regulatory authorities. Fruitflow is the
only natural antiplatelet to have a health claim approved by the
European Food Safety Authority, stating that 150mg of Fruitflow
'helps maintain normal platelet aggregation, which contributes to
healthy blood flow'.
Provexis plc entered into a long-term Alliance Agreement with
DSM Nutritional Products in 2010 to commercialise Fruitflow through
sales as an ingredient to brand owners in the food, beverage and
dietary supplement categories. More than 90 regional consumer
healthcare brands have now been launched by direct customers of
DSM, and a number of further regional brands have been launched
through DSM's distributor channels.
Fruitflow has a number of other specific health benefits which
have been reflected in separate patent filings for the use of
Fruitflow in:
-- mitigating exercise-induced inflammation;
-- managing blood pressure; and
-- protecting against the adverse effects of air pollution on
the body's cardiovascular system. Laboratory work has shown that
Fruitflow can reduce the platelet activation caused by airborne
particulate matter, such as that from diesel emissions, by
approximately one third.
Provexis sells a high quality dietary supplement product
containing Fruitflow and Omega-3 from its separate website
www.fruitflowplus.com on a mail order basis. The product is also
available to purchase from Amazon.co.uk and from Holland &
Barrett.
The Company is working closely with By-Health Co., Ltd, a GBP5bn
listed Chinese dietary supplement business, to support the planned
launch of some Fruitflow based products in the Chinese market. The
planned launch is progressing well with potential sales volumes
remaining at a significant multiple of existing Fruitflow
sales.
By-Health has made a significant investment in eight separate
studies in China, at its sole expense, in support of the Fruitflow
based products which it plans to launch in China.
The five studies which have been completed by By-Health showed
excellent results in use for Fruitflow, and provide strong evidence
for By-Health in its regulatory submissions to the Chinese State
Administration for Market Regulation (SAMR) for Fruitflow.
By-Health is now working on an extensive regulatory submission
to the SAMR for Fruitflow, seeking to establish a new permitted
health function claim for food ingredients such as Fruitflow that
can demonstrate an anti-platelet effect, addressing the aberrant
blood clots which can lead to heart attacks and strokes.
By-Health currently expects to be in a position to complete the
last of its eight studies and file its regulatory submission to the
SAMR for Fruitflow in the first half of 2022. If By-Health is
successful in obtaining a new permitted health function claim it is
currently expected that this would result in some significant
orders for Fruitflow, potentially at a multiple of current total
sales values.
COVID-19
The Company and DSM have experienced increased consumer interest
for Fruitflow in recent months, in light of the COVID-19 pandemic,
as consumers look to nutritional interventions to help them fortify
the circulatory system against the effects of COVID-19. The Company
and DSM will look to maximise the commercial opportunities arising
from this increased consumer interest in Fruitflow, and will
further promote the core blood circulatory and anti-inflammatory
benefits of the product.
In September 2020 Fruitflow was recognised in a review article
by the Frontiers in Nutrition journal
www.frontiersin.org/articles/10.3389/fnut.2020.583080/full which
stated that nutraceuticals such as Fruitflow may serve as:
'A safe antiplatelet prophylactic treatment for those at high
risk of COVID-19 who may also be at increased risk of thrombotic
complications and an alternative to pharmacological compounds that
may cause greater risk of bleeding.'
Provexis was founded in 1999 and is headquartered in Reading,
Berkshire.
Provexis shares are traded on the AIM market of the London Stock
Exchange under the ticker symbol PXS.
For further information, please visit www.provexis.com and
www.fruitflowplus.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHDFLFBFBLBFBL
(END) Dow Jones Newswires
October 01, 2021 13:04 ET (17:04 GMT)
Provexis (AQSE:PXS.GB)
Historical Stock Chart
From Mar 2025 to Apr 2025
Provexis (AQSE:PXS.GB)
Historical Stock Chart
From Apr 2024 to Apr 2025
